Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists.

Vinader V, Ahmet DS, Ahmed MS, Patterson LH, Afarinkia K.

PLoS One. 2013 Oct 18;8(10):e78744. doi: 10.1371/journal.pone.0078744. eCollection 2013.

2.

Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.

Ziarek JJ, Liu Y, Smith E, Zhang G, Peterson FC, Chen J, Yu Y, Chen Y, Volkman BF, Li R.

Curr Top Med Chem. 2012;12(24):2727-40.

3.

Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.

Våbenø J, Haug BE, Rosenkilde MM.

Future Med Chem. 2015;7(10):1261-83. doi: 10.4155/fmc.15.64. Review.

PMID:
26144264
4.

Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.

Cox BD, Prosser AR, Katzman BM, Alcaraz AA, Liotta DC, Wilson LJ, Snyder JP.

Chembiochem. 2014 Jul 21;15(11):1614-20. doi: 10.1002/cbic.201402056. Epub 2014 Jul 2.

5.

Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.

Zhang H, Kang D, Huang B, Liu N, Zhao F, Zhan P, Liu X.

Eur J Med Chem. 2016 May 23;114:65-78. doi: 10.1016/j.ejmech.2016.02.051. Epub 2016 Feb 24. Review.

PMID:
26974376
6.

Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine a as a new CXCR4 ligand exhibiting antagonist activity.

Vitale RM, Gatti M, Carbone M, Barbieri F, Felicità V, Gavagnin M, Florio T, Amodeo P.

ACS Chem Biol. 2013 Dec 20;8(12):2762-70. doi: 10.1021/cb400521b. Epub 2013 Oct 30.

PMID:
24102412
7.

An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics.

Grande F, Giancotti G, Ioele G, Occhiuzzi MA, Garofalo A.

Eur J Med Chem. 2017 Oct 20;139:519-530. doi: 10.1016/j.ejmech.2017.08.027. Epub 2017 Aug 12. Review.

PMID:
28826086
8.

Small molecule inhibitors of CXCR4.

Debnath B, Xu S, Grande F, Garofalo A, Neamati N.

Theranostics. 2013;3(1):47-75. doi: 10.7150/thno.5376. Epub 2013 Jan 15. Review.

9.

Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists.

Mishra RK, Shum AK, Platanias LC, Miller RJ, Schiltz GE.

Sci Rep. 2016 Jul 26;6:30155. doi: 10.1038/srep30155.

10.

Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.

Hatse S, Princen K, Liekens S, Vermeire K, De Clercq E, Schols D.

Cytometry A. 2004 Oct;61(2):178-88.

11.

Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design.

Veldkamp CT, Ziarek JJ, Peterson FC, Chen Y, Volkman BF.

J Am Chem Soc. 2010 Jun 2;132(21):7242-3. doi: 10.1021/ja1002263.

12.

Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA.

Blood. 2005 Sep 1;106(5):1824-30. Epub 2005 May 19.

13.

The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.

Peng D, Cao B, Zhou YJ, Long YQ.

Eur J Med Chem. 2018 Apr 10;149:148-169. doi: 10.1016/j.ejmech.2018.02.043. Epub 2018 Feb 17. Review.

PMID:
29500940
14.

Identifying modulators of CXC receptors 3 and 4 with tailored selectivity using multi-target docking.

Schmidt D, Bernat V, Brox R, Tschammer N, Kolb P.

ACS Chem Biol. 2015 Mar 20;10(3):715-24. doi: 10.1021/cb500577j. Epub 2014 Dec 5.

PMID:
25398025
15.

Development of a unique small molecule modulator of CXCR4.

Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, Klapproth JM, Yang H, Grossniklaus HE, Xu J, Rojas M, Voll RJ, Goodman MM, Arrendale RF, Liu J, Yun CC, Snyder JP, Liotta DC, Shim H.

PLoS One. 2012;7(4):e34038. doi: 10.1371/journal.pone.0034038. Epub 2012 Apr 2.

16.

Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach.

Neves MA, Simões S, Sá e Melo ML.

J Comput Aided Mol Des. 2010 Dec;24(12):1023-33. doi: 10.1007/s10822-010-9393-x. Epub 2010 Oct 20.

PMID:
20960031
17.

CXCR4 Antagonists: A Screening Strategy for Identification of Functionally Selective Ligands.

Castaldo C, Benicchi T, Otrocka M, Mori E, Pilli E, Ferruzzi P, Valensin S, Diamanti D, Fecke W, Varrone M, Porcari V.

J Biomol Screen. 2014 Jul;19(6):859-69. doi: 10.1177/1087057114526283. Epub 2014 Mar 14.

PMID:
24632660
18.

Structural analysis of a novel small molecule ligand bound to the CXCL12 chemokine.

Smith EW, Liu Y, Getschman AE, Peterson FC, Ziarek JJ, Li R, Volkman BF, Chen Y.

J Med Chem. 2014 Nov 26;57(22):9693-9. doi: 10.1021/jm501194p. Epub 2014 Nov 13.

19.

Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.

Zabel BA, Wang Y, Lewén S, Berahovich RD, Penfold ME, Zhang P, Powers J, Summers BC, Miao Z, Zhao B, Jalili A, Janowska-Wieczorek A, Jaen JC, Schall TJ.

J Immunol. 2009 Sep 1;183(5):3204-11. doi: 10.4049/jimmunol.0900269. Epub 2009 Jul 29.

20.

Structure-based development of antagonists for chemokine receptor CXCR4.

Zhang C, Hou T, Feng Z, Li Y.

Curr Comput Aided Drug Des. 2013 Mar;9(1):60-75. Review.

PMID:
22734712

Supplemental Content

Support Center